--- title: "Surrozen (SRZN) news: offering" url: "https://aibio.space/companies/surrozen/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SRZN offering news: Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross. Surrozen, Inc." --- SRZN Surrozen, Inc. NASDAQ · United States # Surrozen (SRZN) news SRZN offering news Financings · 2026-10-20 ## [Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross](https://aibio.space/news/surrozen-closes-second-tranche-march-2025-private-placement-about-95-1/) Surrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029. ## Latest Surrozen news 1. 2026-10-20 Financings [Surrozen closes $95.1 million second tranche of March 2025 private placement](https://aibio.space/news/surrozen-closes-95-1-million-second-tranche-march-2025-private/) The second tranche brought in about $95.1 million gross, before placement agent fees, and the company expects cash to last into 2029. The first patient in its SZN-8141 trial is not expected to be dosed until the fourth quarter of 2026, after a rival Wnt drug met its primary endpoint in a Phase 2b/3 trial in the same eye disease. 2. 2026-10-02 Financings [Surrozen IND clearance sets up expected $95.1 million second private placement closing](https://aibio.space/news/surrozen-ind-clearance-sets-up-expected-95-1-million-second-private/) FDA clearance of the SZN-8141 IND satisfies the second closing milestone in Surrozen's March 2025 private placement, which is expected to bring about $95.1 million gross on or about October 20, 2026. First patient dosing is not expected until the fourth quarter of 2026, with initial data in the second half of 2027. 3. 2025-03-28 Financings [Surrozen closes first tranche of private placement for about $76.4 million in gross proceeds](https://aibio.space/news/surrozen-closes-first-tranche-private-placement-about-76-4-million/) Surrozen sold 6,586,415 units in a first closing on March 26, 2025, for about $76.4 million gross before fees. Placement agent Guggenheim Securities, LLC was named in the purchase agreement. A second closing of about $98.6 million depends on FDA clearance of the SZN-8141 IND by October 31, 2026. ## Surrozen at a glance - **Ticker**: SRZN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $102.0 million ### Related companies - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) NASDAQ: IOVA - [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE - [Vistagen Therapeutics](https://aibio.space/companies/vistagen-therapeutics/) NASDAQ: VTGN - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) OTC: CALA - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) NASDAQ: BMRN - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) NASDAQ: RLAY - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX ### Also on NASDAQ - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NTHI - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) ANTX - [Profusa](https://aibio.space/companies/profusa/) PFSA - [OneMedNet](https://aibio.space/companies/onemednet/) ONMD - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK - [CYPHERPUNK TECHNOLOGIES INC.](https://aibio.space/companies/cypherpunk-technologies/) CYPH ## Surrozen annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | | Research and development | [$29.4 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | [$21.1 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | | Net income (loss) | [-$242.0 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | [-$63.6 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | | Cash from operations | [-$30.2 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | [-$17.6 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | | Cash and equivalents | [$89.2 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526338120/) | [$34.6 million](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $102.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Surrozen Has Surrozen raised money recently? Our latest story on this, dated Oct 20, 2026: "Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/surrozen-closes-second-tranche-march-2025-private-placement-about-95-1/). What is the ticker symbol of Surrozen? Surrozen, Inc. trades under the ticker SRZN on NASDAQ. Where is Surrozen listed? Surrozen, Inc. is listed on NASDAQ. What is the SEC CIK of Surrozen? The SEC Central Index Key (CIK) for Surrozen, Inc. is 1824893. Its filings are on SEC EDGAR. How many shares does Surrozen have outstanding? 11,753,558 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Surrozen listed under? Our directory records Surrozen, Inc. under United States. What does Surrozen do? Our directory classifies Surrozen, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Surrozen? The ISIN recorded for Surrozen, Inc. is US86889P2083. Does aibio.space cover Surrozen? aibio.space lists Surrozen, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Surrozen incorporated? SEC records list its state or country of incorporation as DE. What was Surrozen's revenue last year? $3.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Surrozen profitable? Surrozen, Inc. reported a net loss of $242.0 million for the fiscal year ended Dec 31, 2025, and used $30.2 million of cash in operations, per its annual report to the SEC. How much does Surrozen spend on research and development? $29.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Surrozen have? $102.0 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Surrozen (SRZN) stock news? Our latest story on Surrozen, dated Oct 20, 2026: "Surrozen closes second tranche of March 2025 private placement for about $95.1 million gross". Surrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029. [Source](https://aibio.space/news/surrozen-closes-second-tranche-march-2025-private-placement-about-95-1/). ## Investor discussion: Surrozen Members talk about Surrozen (SRZN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Surrozen, newest first. Each line links the filing it comes from. 1. 2026-10-20 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/srzn-ex99_1.htm) 2. 2026-10-02 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/srzn-20261002.htm) 3. 2026-03-23 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1824893/000119312526120016/srzn-20260323.htm) 4. 2025-10-17 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1824893/000119312525242518/srzn-20251014.htm) 5. 2025-08-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1824893/000095017025112251/srzn_424b5_20250829.htm) 6. 2025-05-20 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1824893/000095017025075238/srzn_s-3_shelf_202505.htm) 7. 2025-04-24 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1824893/000095017025058037/srzn_424b5_20250424.htm) 8. 2025-03-24 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/d923940dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SRZN on TradingView](https://www.tradingview.com/symbols/NASDAQ-SRZN/). ## SEC filings and registration - **SEC name**: Surrozen, Inc./DE - **CIK**: 1824893 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SRZN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-475-2820 - **Shares outstanding**: 11,753,558 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: Consonance-HFW Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1824893/000119312526426828/srzn-20261020.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1824893/000119312526411298/srzn-20261002.htm) filed 2026-10-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1824893/000119312526338120/srzn-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1824893/000119312526224037/srzn-20260513.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1824893/000119312526209179/srzn-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1824893/000119312526208999/srzn-20260506.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1824893/000119312526137976/srzn-20260401.htm) filed 2026-04-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001824893), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Surrozen, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SRZN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Surrozen, Inc. - **Ticker**: SRZN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US86889P2083 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SRZN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/surrozen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Surrozen (SRZN) news: offering", 2026-10-31, https://aibio.space/companies/surrozen/